Morgan Lee Lekstrom Buys 50,000 Shares of Biosig Technologies (NASDAQ:STEX) Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom acquired 50,000 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The shares were purchased at an average cost of $0.99 per share, with a total value of $49,500.00. Following the transaction, the chairman directly owned 359,500 shares of the company’s stock, valued at $355,905. This trade represents a 16.16% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Thursday, May 28th, Morgan Lee Lekstrom acquired 34,000 shares of Biosig Technologies stock. The shares were purchased at an average cost of $1.47 per share, with a total value of $49,980.00.
• On Thursday, May 21st, Morgan Lee Lekstrom acquired 147,000 shares of Biosig Technologies stock. The shares were purchased at an average cost of $1.04 per share, with a total value of $152,880.00.
• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The stock was sold at an average price of $1.07, for a total transaction of $13,652.13.

Biosig Technologies Stock Up 6.5%

STEX traded up $0.06 on Monday, hitting $1.04. 1,331,623 shares of the stock were exchanged, compared to its average volume of 1,856,985. Biosig Technologies, Inc. has a 12 month low of $0.70 and a 12 month high of $14.11. The company has a 50-day moving average of $1.07. The firm has a market capitalization of $188.17 million, a price-to-earnings ratio of -0.11 and a beta of 1.85.

Biosig Technologies (NASDAQ:STEX) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.27) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Needham & Company LLC dropped their target price on shares of Biosig Technologies from $9.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, May 21st. Wall Street Zen cut shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a report on Sunday, April 5th. Finally, Weiss Ratings raised shares of Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.00.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.